However, better understanding is needed as to the role of DUX4 in health and its contribution to non‐FSHD disorders, in addition to whether DUX4 expression directly contributes to ongoing pathology and so is practical to target as an FSHD therapy. The gene discussed is DUX4; the disease is Facioscapulohumeral dystrophy.